Matthew Durdy

Matthew Durdy is an accomplished executive with extensive experience in the biotechnology and finance sectors. Currently serving as Chief Executive at Cell and Gene Therapy Catapult since January 2013, Matthew is responsible for developing and implementing strategic initiatives, overseeing business development, and managing stakeholder engagement. Additionally, Matthew holds leadership positions as Chair of Parkinson's Research Ventures Limited and Board Trustee for Parkinson's UK. Previous roles include Chief Executive at Aqix Limited and Managing Director at Biotec Laboratories Ltd, where significant improvements in strategy and funding were achieved. Matthew's early career includes key positions at CDC Group plc and Bank of America, with a strong educational background from The University of Chicago Booth School of Business and the University of Oxford.